NCT00112671 2018-07-27
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
6 trialsNCT00461851 2017-12-14
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
Yale University
Phase 2 Completed
NCT00714948 2015-11-16
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00112905 2014-05-30
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01222676 2013-08-12
Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01215266 2011-09-08
Sorafenib in Urothelium Cancer of Bladder
Association of Urologic Oncology (AUO)
Phase 2 Terminated